Antengene Corporation Limited
HHKEX:6996Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Semi-annual Revenue
•
in mil. unless spec.Semi-annual Earnings Per Share
•
in mil. unless spec.Semi-annual Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Jian Ming Mei
- Full Time Employees
- 129
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Zhongshan SOHO Plaza Suzhou SH China 200051
- IPO Date
- Nov 20, 2020
- Website
- antengene.com
- Similar Companies
- Business
- Antengene Corporation Limited (SEHK: 6996.HK) is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class and best-in-class oncology therapies, including small molecules, antibody-drug conjugates, bispecific antibodies, and monoclonal antibodies; its commercialized asset is ATG-010 (selinexor, branded XPOVIO® and 希維奧® in Greater China), an oral selective inhibitor of nuclear export (XPO1/SINE compound) approved for relapsed/refractory multiple myeloma, diffuse large B-cell lymphoma and other hematological malignancies; APAC rights assets also include ATG-008 (sunitinib), a second-generation mTORC1/2 inhibitor in trials for cervical cancer and other solid tumors; global rights pipeline encompasses ATG-022 (Claudin 18.2 ADC) in Phase II for gastric/gastroesophageal junction adenocarcinoma including ultra-low expressors, ATG-037 (CD73 small molecule inhibitor) in combination with pembrolizumab for solid tumors, ATG-101 (PD-L1 x 4-1BB bispecific antibody) in Phase I, ATG-031 (anti-CD24 monoclonal antibody) in Phase I for solid tumors, ATG-042 (PRMT5-MTA small molecule inhibitor) in preclinical stage, ATG-201 (CD19 x CD3 TCE 2.0) advancing toward clinical trials in 2025, alongside the proprietary AnTenGager™ TCE 2.0 platform featuring steric hindrance-masking technology for solid tumors, hematological malignancies and autoimmune diseases, which is open for co-discovery, co-development, antibody integration and licensing collaborations. Founded in 2017 and headquartered in Shanghai, China, with subsidiaries and operations in Hong Kong, South Korea, Australia, Singapore and the United States, Antengene serves cancer patients across Greater China, Australia, South Korea, Taiwan, ASEAN countries and pursues global expansion through R&D, clinical trials and commercialization in hematologic malignancies and solid tumors targeting oncologists, hematologists and healthcare systems. Recent developments include a global clinical collaboration with MSD in May 2025 to evaluate ATG-022 combined with KEYTRUDA® (pembrolizumab) in advanced solid tumors; Breakthrough Therapy Designation granted to ATG-022 by China's NMPA for gastric/gastroesophageal junction adenocarcinoma; a strategic alliance with Hansoh Pharma for up to RMB100 million upfront plus RMB535 million milestones on selinexor commercialization in Mainland China while retaining sales revenues; advancement of AnTenGager™ TCE 2.0 with ATG-201 poised for clinical entry in the second half of 2025 and active pursuit of global partnerships for the platform; positive mid/late-stage data highlighted in 2025 interim results alongside robust pipeline progress; and ongoing expansion of manufacturing capabilities including a new China plant in Shaoxing.
Company News
Antengene Announces Clinical Collaboration with Junshi Biosciences to Explore the Synergistic Potential of ATG-037 (Oral CD73 Inhibitor) In Combination with JS207 (PD-1/VEGF BsAb)
Junshi Biosciences Announces Strategic Collaboration with Antengene to Evaluate Combination Therapy with JS207 (PD-1/VEGF BsAb) and ATG-037 (Oral CD73 Inhibitor)
Antengene's ATG-022 (CLDN18.2 ADC) Granted Breakthrough Therapy Designation for the Treatment of Gastric/Gastroesophageal Junction Adenocarcinoma
XPOVIO® (selinexor) Approved for Commercialization in Indonesia, Further Expanding Antengene's Commercial Presence in APAC
Antengene Announces XPOVIO® Approved for Public Health Insurance Coverage in Taiwan Market, Benefiting More Patients with R/R MM in the Region
Antengene to Present Results from Two Late-Stage Studies of Selinexor Signaling Potential Clinical Breakthrough at ASH 2024
Antengene Announces XPOVIO® (selinexor) Approved for Its Third Indication in South Korea, Bringing Fresh Hope to Patients with MM in the Country
Antengene Announces XPOVIO® (selinexor) Approved for Commercialization in Thailand
Antengene Announces XPOVIO® (selinexor) Approved for Commercialization in Malaysia
Antengene Announces XPOVIO® (selinexor) National Health Insurance Service Approval for Reimbursement in South Korea
Antengene Announces ATG-101 Granted Orphan Drug Designation by the U.S. FDA
Week In Review: Antengene Approved By Hong Kong Exchange For $200 Million IPO